Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes
In this study, treatment with tirzepatide was associated with lower hazards of all-cause mortality, adverse cardiovascular events, acute kidney injury, and adverse kidney events compared with GLP-1 RA in patients with type 2 diabetes. These findings support the integration of tirzepatide into therapeutic strategies for this population.
Authors
- Vin‐Cent Wu (ORCID: https://orcid.org/0000-0001-7935-0991)
- Zheng-Hong Jiang
- Jui‐Yi Chen (ORCID: https://orcid.org/0000-0003-1376-7780)
- Min‐Hsiang Chuang (ORCID: https://orcid.org/0000-0002-8538-4861)
- Hsien‐Yi Wang
Institutions
- National Taiwan University Hospital (TW)
- Chi Mei Medical Center (TW)
- Chia Nan University of Pharmacy and Science (TW)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2024-08-12
- DOI
- https://doi.org/10.1001/jamanetworkopen.2024.27258
- Citations
- 95
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 33.98